Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
MWN-AI** Summary
Idorsia Ltd (SIX: IDIA) has announced significant new insights regarding aprocitentan, its dual endothelin receptor antagonist, which will be presented at the 2025 American Society of Nephrology (ASN) Kidney Week and the American Heart Association (AHA) Scientific Sessions. The data comes from the Phase 3 PRECISION study, particularly focusing on patients with resistant hypertension and high cardiovascular risk, including those with chronic kidney disease.
One of the forthcoming poster presentations, titled “Is Aprocitentan's Effect on Albuminuria Merely Due to Lowered BP? Subgroup Analysis of the PRECISION Trial,” will highlight findings that demonstrate aprocitentan’s ability to significantly lower systolic blood pressure and the Urine Albumin-to-Creatinine Ratio (UACR) in patients already taking at least three antihypertensive medications. Notably, the reductions in UACR were found to be independent of blood pressure reductions, indicating that aprocitentan may offer renal protective benefits through additional mechanisms, such as altering glomerular permeability and inducing post-glomerular vasodilation.
Alongside its presence at ASN Kidney Week, Idorsia will participate in the AHA Scientific Sessions 2025, hosting a symposium titled ‘The Next Era in the Treatment of Hypertension.’ Dr. Michael Bloch from the University of Nevada will present further insights from the PRECISION trial during this session.
Aprocitentan, marketed in the U.S. as TRYVIO® since October 2024, is a promising treatment for systemic hypertension and is included in new clinical practice guidelines from the American College of Cardiology and the AHA. In the European Union, it is approved as JERAYGO® for resistant hypertension. With a commitment to innovative medical solutions, Idorsia continues to build its reputation as a leading biopharmaceutical company focused on transformative treatments.
MWN-AI** Analysis
As Idorsia Ltd (SIX: IDIA) prepares to present exciting new data on aprocitentan at both the ASN Kidney Week and AHA Scientific Sessions, the company is positioned at a pivotal moment in its growth trajectory. The latest analysis from the Phase 3 PRECISION study underscores aprocitentan’s considerable potential in managing resistant hypertension in patients with chronic kidney disease, a demographic often overlooked in hypertension therapies.
The findings highlight that aprocitentan not only effectively lowers blood pressure but also reduces albuminuria—a key indicator of kidney damage. The ability of aprocitentan to achieve significant reductions in the Urine Albumin-to-Creatinine Ratio (UACR) suggests that its benefits extend beyond mere blood pressure control. This positions aprocitentan as a truly innovative player in the treatment landscape for patients at high cardiovascular risk.
Investors should closely monitor the outcomes of these presentations, particularly the potential implications for the US and European markets, where aprocitentan is already gaining traction. Its inclusion in the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines further solidifies its status and could drive adoption among healthcare professionals.
With a robust drug pipeline and a commitment to innovative treatments, Idorsia’s strategy appears effective in addressing unmet medical needs. Potential catalysts such as global regulatory approvals and continued positive clinical data may enhance the company’s market position, inviting interest from both healthcare providers and investors.
The current market sentiment around cardiovascular therapies makes Idorsia an attractive consideration for those looking to invest in the biopharmaceutical sector. A strategic buy on the stock anticipated following these conferences could yield dividends, particularly as the medical community recognizes the full clinical potential of aprocitentan.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high cardiovascular risk – including chronic kidney disease
Allschwil, Switzerland – November 05, 2025
Idorsia Ltd (SIX: IDIA) shares that new analysis of the landmark Phase 3 PRECISION study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of Nephrology (ASN) Kidney Week 2025 , taking place in Houston, TX, November 5–9, 2025.
A poster presentation entitled “ Is Aprocitentan's Effect on Albuminuria Merely Due to Lowered BP? Subgroup Analysis of the PRECISION Trial ” will be held in the Hypertension and CVD: Clinical – 1 session on November 6, at 10:00-12:00 CT ( Abstract ). The poster highlights that aprocitentan, in addition to at least three antihypertensives, substantially reduced systolic blood pressure and Urine Albumin-to-Creatinine Ratio (UACR) versus placebo across all subgroups with renal impairment and resistant hypertension. The correlation analysis shows that the highly significant reductions in blood pressure with aprocitentan do not solely explain the observed reductions in UACR, suggesting that additional mechanisms are involved in aprocitentan’s renal-protective effect, such as a decrease in glomerular permeability, post-glomerular vasodilation or functional tubular changes.
In addition, Idorsia will be present at The American Heart Association (AHA) Scientific Sessions 2025 , taking place in New Orleans, LA, November 7–10, 2025, with a sponsored educational symposium entitled ‘The Next Era in the Treatment of Hypertension’ . The symposium will take place in Learning Studio 1 on November 9, at 9:30am - 10:15am CT. Dr Michael Bloch, Associate Professor, Department of Internal Medicine at University of Nevada School of Medicine and Medical Director of Vascular Medicine and Anticoagulation Services at the Renown Medical Center Institute for Heart and Vascular Health, will present data from the PRECISION trial and discuss the use of aprocitentan in clinical practice.
Notes to the editor
About aprocitentan
Aprocitentan is Idorsia’s once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan is approved as TRYVIO ® in the US for the treatment of systemic hypertension in combination with other antihypertensives and has been commercially available since October 2024. For more information see the Full Prescribing Information including BOXED Warning ( PI and Medication Guide ). TRYVIO is now included in the American College of Cardiology’s (ACC) and the American Heart Association’s (AHA) new comprehensive clinical practice guidelines for the management of high blood pressure. Aprocitentan is approved as JERAYGO ® for the treatment of resistant hypertension in combination with other antihypertensives in the European Union, the UK, and Switzerland, and a marketing authorization application is under review in Canada.
About Idorsia
The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients.
Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).
For further information, please contact:
Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Attachment
FAQ**
How do the new findings from the PRECISION study on aprocitentan impact the perceived value of Idorsia Ltd Registered Shares IDRSF in the biopharmaceutical market focused on hypertension treatments?
What are the potential implications of aprocitentan’s dual mechanism of action on its long-term market performance, and how might this affect investor confidence in Idorsia Ltd Registered Shares IDRSF?
In light of the American Heart Association’s inclusion of aprocitentan in their treatment guidelines, how could this enhance the market position of Idorsia Ltd Registered Shares IDRSF among investors and healthcare professionals?
Given that aprocitentan has shown renal-protective effects beyond ???? lowering blood pressure, what might this suggest about the future development pipeline and strategy for Idorsia Ltd Registered Shares IDRSF?
**MWN-AI FAQ is based on asking OpenAI questions about Idorsia Ltd Registered Shares (OTC: IDRSF).
NASDAQ: IDRSF
IDRSF Trading
0.0% G/L:
$5.16 Last:
1,502 Volume:
$5.16 Open:
